The Guardian: What does new drug PaMZ mean for TB and HIV treatment?
“Earlier this year, the TB Alliance announced that it was ready to start clinical trials for PaMZ, its new tuberculosis (TB) drug. PaMZ is a combination of three drugs, two of which have not been licensed for TB treatment before. … To find out more about the potential value of the new drug, we asked four professionals what impact they see it having on their work…” (Filou, 8/26).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.